Drugs / BVAC-C
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02866006 | Oct 2016 → Dec 2021 | cervical cancer | Cellid Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04800978 | Jun 2021 → Aug 2024 | cervical cancer | Samsung Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BVAC-C | “BVAC-C BVAC-C will be supplied in cyclic olefin co-polymer vials containing 1x10⁸ cells of suspension at a concentration of 5x10⁷ cells/mL infusion” NCT04800978 ↗ |
| Modality | Vaccine | “BVAC-C, a B cell- and monocyte-based immunotherapeutic vaccine transfected with recombinant HPV E6/E7” PMID 38605958 ↗ Mar 2024 |
| Route | Intravenous | “BVAC-C IV injection at 0, 4, 8th weeks.(HIgh dose)” NCT02866006 ↗ |